Previous 10 | Next 10 |
CorMedix, Inc. (CRMD) Q4 2019 Earnings Conference Call March 16, 2020 4:30 PM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Khoso Baluch - Chief Executive Officer Phoebe Mounts - Executive Vice President and General Counsel Conference Call Participan...
CorMedix (NYSEMKT: CRMD ): Q4 GAAP EPS of -$0.21 beats by $0.03 . More news on: CorMedix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company in process of submitting New Drug Application (NDA) for Neutrolin ® for prevention of catheter-related blood stream infections via a rolling review granted by FDA Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., March 16, 2020 (G...
BERKELEY HEIGHTS, N.J., March 06, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will re...
The New Jersey Economic Development Authority has signed off on the sale of ~$5.5M of net operating loss (NOL) tax credits owned by CorMedix (NYSEMKT: CRMD ) to an unnamed profitable New Jersey-based company. More news on: CorMedix, Inc., Healthcare stocks news, Read more ...
BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been...
BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food...
Allogene Therapeutics (NASDAQ: ALLO ) initiated with Market Perform rating and $37 (36% upside) price target at JMP Securities. More news on: Allogene Therapeutics, Inc., CorMedix, Inc., Fortress Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test now using the top four forensic algorithms applied to detect bankruptcy risk, earnings manipulation, and financial irregularities. This forward testing study co...
CorMedix, Inc. (CRMD) Q3 2019 Earnings Conference Call November 14, 2019 16:30 ET CompanyParticipants Dan Ferry - MD, LifeSci Advisors Khoso Baluch - CEO Phoebe Mounts - EVP & General Counsel Jack Armstrong - EVP, Technical Operations Bob Cook - CFO Conference Call Par...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...